SII, Symbiosis to set up research centre for vaccine development

Serum Institute of India on Friday said it has signed an agreement with the Symbiosis International University earlier this month to set up a research centre for vaccines and biologicals.

The R&D (Research & Development) centre will lead the development of new vaccines, technologies, products and innovations in immunisation practices that provide equitable access to life-saving interventions, especially across Low- and Middle-Income Countries (LMICs). The entity will work towards improving health equity against future pandemics and infectious diseases.

It will also ensure cross-programme coordination and collaboration, as the facility will be an ecosystem that would also have R&D centres for stem cells, nanotechnology, medical image analysis, applied artificial intelligence and waste resource management, among others.

“The research centre will be instrumental in advancing indigenous capabilities for end-to-end development of any futuristic technology and projects in the field of vaccines and biologics in collaboration with global partners,” Serum Institute CEO Adar Poonawalla said in a statement.

Symbiosis International University’s faculty of health sciences dean Rajiv Yeravdekar said the initiative will help not only in addressing futuristic innovations but also needs of LMIC specific diseases.

“We look forward to get the best available talent and equip them with the latest technology that facilitates global partnerships and collaborations. It will also abode a galaxy of scientists over the next 5-7 years and aim to be a front runner in building an equitable universal health framework,” he added.

Serum Institute of India is the world’s largest company in terms of COVID-19 vaccine production having manufactured over 500 million doses.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor